TECHEU VD BREYE (BIOTECH ACT)
Sector: Industry • Location: Denmark
Source: European Investment Bank (EIB)
The project supports Breye Therapeutics, a Danish clinical-stage biotech that is developing first-in-class oral therapies for retinal diseases.
Its lead programme, Danegaptide, targets diabetic retinopathy by stabilising retinal vasculature and reducing disease progression, while a second programme develops P2X7 receptor antagonists for age-related macular degeneration and other retinal disorder
- Status
- Prospective
- Sector
- Industry
- Location
- Denmark
- Updated
- 19 Nov 2026
- Source
- European Investment Bank (EIB)
ConstructChat
Ask ConstructChat about TECHEU VD BREYE (BIOTECH ACT)
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | under appraisal |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | The project supports Breye Therapeutics, a Danish clinical-stage biotech that is developing first-in-class oral therapies for retinal diseases. Its lead programme, Danegaptide, targets diabetic retinopathy by stabilising retinal vasculature and reducing disease progression, while a second programme develops P2X7 receptor antagonists for age-related macular degeneration and other retinal disorders. |
Original sector | Industry |
Location
Country | Denmark |
Source
Source | European Investment Bank (EIB) |
URL |
More Details
Record type | Project |
Article published date | 2026-11-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
